Phreesia, Inc. (NYSE:PHR – Get Free Report) COO Evan Roberts sold 3,148 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total value of $73,191.00. Following the completion of the sale, the chief operating officer now owns 755,719 shares in the company, valued at approximately $17,570,466.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Evan Roberts also recently made the following trade(s):
- On Tuesday, July 16th, Evan Roberts sold 1,669 shares of Phreesia stock. The stock was sold at an average price of $23.74, for a total value of $39,622.06.
Phreesia Trading Up 3.9 %
Phreesia stock opened at $24.68 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77. The stock has a market cap of $1.42 billion, a PE ratio of -11.37 and a beta of 0.93. The stock has a 50-day moving average of $23.72 and a two-hundred day moving average of $22.75. Phreesia, Inc. has a one year low of $12.05 and a one year high of $29.16.
Hedge Funds Weigh In On Phreesia
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on PHR shares. Royal Bank of Canada restated a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a report on Thursday, September 5th. Truist Financial boosted their price target on shares of Phreesia from $29.00 to $31.00 and gave the company a “buy” rating in a report on Friday, September 6th. Needham & Company LLC reissued a “buy” rating and set a $29.00 price objective on shares of Phreesia in a report on Thursday, September 5th. KeyCorp lowered their target price on Phreesia from $27.00 to $25.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Finally, JPMorgan Chase & Co. increased their target price on Phreesia from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Monday, September 9th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Phreesia currently has an average rating of “Moderate Buy” and an average price target of $29.42.
View Our Latest Research Report on Phreesia
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
See Also
- Five stocks we like better than Phreesia
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- Manufacturing Stocks Investing
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.